Pegcetacoplan for Prophylaxis Against C3 Glomerulopathy Recurrence After a Second Kidney Transplantation in a High-Risk Patient (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0801; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Two months after transplantation, disease recurrence was diagnosed and eculizumab treatment was initiated, resulting in normalization of proteinuria and kidney function...Treatment with oral iptacopan was initiated without improvement, and severe prolonged diarrhea developed...Treatment with proximal complement inhibitors may prevent C3G recurrence. Longer follow-up and further studies are needed to establish the safety and efficacy of this therapeutic approach."
Clinical • Complement-mediated Rare Disorders • Glomerulonephritis • Nephrology • Transplantation
|
|
Yael Borovitz; Ruth Rahamimov
|